Akin: Cannabis in 2024: HHS Rescheduling Recommendation and SAFER Banking
Key Points The scientific review supporting HHS’s recommendation to DEA that cannabis be reclassified from a Schedule I to a Schedule III drug was published on January 12, 2024. Classifying cannabis as a Schedule III substance would have significant implications for...
mcglinchey: Hemp Industry 2024: State and Federal Changes
By Brittany Adikes & Heidi Urness on February 21, 2024 As an increasing number of states across the U.S. are becoming marijuana-friendly, many states are simultaneously attempting to enact more restrictive laws with respect to hemp-derived cannabinoids....
BGM: Difference Between Delta 8 and Delta 9 THC: Tax and Legal Compliance
In the cannabis industry, business owners must stay informed about the products they deal with and their financial implications. Two cannabinoids that have been the subject of much discussion are Delta-8 and Delta-9 tetrahydrocannabinol (THC). While they may share...
Osborne Clarke: From Hemp To Highs: An Overview Of Cannabis And CBD Legislation Across Europe
15 February 2024 by Osborne Clarke Osborne Clarke Debate and controversy around cannabis and its derivatives are nothing new, with a wide array of legal frameworks and restrictions on its use in place around the world. In Europe, moves to change the legal status of...
Burns Levinson: An Introduction to Rescheduling Realities
For many, the most exciting prospect in the cannabis industry for 2024 is the possibility of rescheduling cannabis from a Schedule I controlled substance to Schedule III under the Controlled Substances Act (as amended and in effect, the “CSA”). Rescheduling would be a...Top 200 Cannabis Lawyers
We Support